Below is last week's news and the YTD performance of the best-performing stocks within the fledgling but burgeoning psychedelic bio-pharmaceutical drug stocks sector.

There are 30 companies and they are divided into 3 categories: the 15 constituents in the munKNEE Pure-Play Psychedelic Drug Stocks Index, the 3 largest cap companies, and 12 other smaller cap companies. All prices are in USD unless otherwise noted (Go here to convert to another currency). 6 marginal companies, as noted below, are excluded from the analysis.

In addition, every company name has been hyperlinked to its corporate web site and every company trading symbol has been hyperlinked to provide stock charts, in-depth financial data, and links to other articles on the company to enable the reader to do their due diligence before making a decision to invest in any stock mentioned above. Also keep in mind that many stocks in this sector trade for less than $1/share (i.e. are penny stocks) and may be susceptible to manipulation by unscrupulous speculators.

The 15 constituent munKNEE Pure-Play Psychedelic Drug Stocks Index is up 54% YTD. If Jaguar's out-sized increase of +300% was excluded from the comparison then the Index only went up by 33% YTD.

The biggest winners YTD are, in descending order, as follows:

1. Jaguar Health (JAGX) +300% to $3.24/share
   • announced that it had sold a secured promissory note of $6M to Streeterville Capital which was also given the right to 18% of the gross proceeds from the sale of a possible tropical disease priority review voucher that Jaguar's subsidiary, Napo Pharmaceuticals, plans to pursue as incentive for the development of Napo's lechlemer drug product candidate for symptomatic relief of inflammatory diarrhea in cholera patients.
   • announced that it would be hosting a webcast on Wednesday, January 27 to provide an update regarding the potential merger of Napo EU, an anticipated subsidiary of the Company in Italy, with a proposed Post Pandemic Recovery Equity special purpose acquisition company.
2. Red Light Holland (TRUFF) +71% to $0.41/share 
   • announced that it was planning to expand distribution of its recreational grade psychedelic Magic Truffles beyond its current legal adult-use market in the Netherlands as legislation around the world changes allowing for use of such products.
3. PharmaTher  (CSE: PHRM; OTCQB: PHRRF) +67% to C$0.40/share
   • announced that it has entered into an exclusive worldwide license agreement with the National Health Research Institutes for the development and commercialization of a patented combination formulation of FDA-approved ketamine and betaine (KETABET™) as a potential next-generation ketamine treatment for mental health, neurological, and pain disorders.
   • announced that it would seek FDA approval to conduct a Phase II clinical study for KETABET™ targeting the more than 300 million people who suffer from major depressive disorder and 100 million people who are resistant to available treatments worldwide.
4. Seelos Therapeutics (SEEL) +64% to $2.59/share
   • announced the previous week that it has received a Notice of Allowance from the Japanese Patent Office covering Trehalose (SLS-005) for the treatment of protein aggregation myopathic and neuro-degenerative diseases by parenteral administration.
5. Numinus Wellness (LKYSF) +49% to $1.25/share
   • announced that it would be listing its warrants for trading on the TSXV effective January 25th under the symbol NUMI.WS pursuant to the Company’s previously announced prospectus offering that closed on December 29, 2020. Each Warrant entitles the holder thereof to acquire one common share of the Company at an exercise price of $0.90 until December 29, 2022.
6. Psyched Wellness (PSYCF) +27% to $0.28/share
   • announced that it had received approval to commence trading in the U.S. markets via the OTCQB under the new ticker symbol PSYCF (formerly DCNPF).
   • announced that it had increased the size of its previously announced bought deal private placement with Canaccord Genuity Corp. for its purchase of an aggregate of ~17.75M units at a price of C$0.31 per unit for gross proceeds of ~C$5.5M which will be used to fully fund the pre-clinical trials of its Amanita Muscaria extract, AME-1 and to continue its scientific research of AME-1 and its potential benefits for people suffering from serious mental and physical health issues and for general corporate purposes.
7. Cybin (CLXPF) +23% to $1.85/share
   •  announced that it had increased the size of its previously announced CDN$20M "bought deal" offering of units from 8.9M units to 13.3M units with Canaccord Genuity Corp  agreeing to purchase the entire offering at a price of CDN$2.25 per Unit for aggregate gross proceeds of CDN$30M
8. Mydecine Innovations (MYCOF) +20% to $0.42/share
   • announced that it had entered into an underwriting agreement with Canaccord Genuity Corp. whereby Canaccord agreed to purchase, on a bought deal basis, an aggregate of 30M units of the Company at a price of C$0.50 per Unit for aggregate gross proceeds to the Company of C$15M.

The remaining 7 constituents have been less active since the beginning of the year performing as follows: Champignon Brands (SHRMF) +3% to $0.64/share; Mind Cure Health (MCURF) +2% to $0.58/share; Havn Life  (HAVLF) N/C @ $0.77/share; Tryp Therapeutics (TRYP) N/C @ C$0.75/share; Revive Therapeutics (RVVTF) -4% to $0.46/share; Mindset Pharma (MSET) -5.3% to C$0.89/share; and Silo Pharma (SILO) -16.7% to $0.35/share

Larger Capitalized Psychedelic Drug Stocks

1. Compass Pathways (CMPS) +1.4% to $48.32/share
   • established its first Centre of Excellence in collaboration with The Sheppard Pratt Institute in Baltimore, Maryland, to accelerate research and improve patient experience in mental health care. Its initial research will focus on COMPASS’s investigational COMP360 psilocybin therapy, which comprises administration of COMP360 psilocybin with psychological support from specially trained therapists.
2. Field Trip Health (FTRPF) +19.1% to $3.87/share
   • no news in the last week
3. Mind Medicine (MMEDF) +19.0% to $3.63/share
   • announced the start of the first ever clinical trial measuring and evaluating MDMA and LSD used in combination in the human body at the University Hospital Basel Liechti Lab, in Basel, Switzerland.

Nano-Cap Psychedelic Drug Stocks

The biggest winners YTD (and their latest news) are as follows:

1. Novamind (NM) +36.0% to C$1.70/share
   • announced the appointment of Pierre Bou-Mansour, P.Eng. to the role of Chief Operating Officer, effective immediately.
2. Ehave (EHVVF) +33.3% @ $0.16/share
   • announced that it had closed the transaction to sell 100% of its Mycotopia Therapy subsidiary to 20/20 Global Inc. (OTC Pink: TWGL) which then plans to change its name to Mycotopia Therapy.
   • announced that it had completed the transaction to acquire the assets of IV therapy service CureDash which will become the backbone of KetaDASH, a platform for medical practitioners to administer ketamine intravenously to patients at home.
3. New Wave Holdings (TRMNF) +25.0% to $0.10/share
   • announced the appointment of Iman Navab to its expert advisory board to provide innovative guidance and insight to support the company's continued growth and development.
   • announced that it had agreed to acquire 100% of Way of Will Inc.
4. Entheon Biomedical (ENTBF) +24.7% to $0.91/share
   • announced a partnership with Divergence Neuro Technologies Inc. to research and develop N-Dimethyltryptamine (DMT) biomarkers and a predictive model of biomarker responses to drug dosage and delivery of DMT-based psychedelic therapeutic products targeted to treat a number of different addiction and substance use disorders.
5. Core One Labs (CLABF) +21.4% to $0.85/share
   • announced that its wholly-owned subsidiary, Vocan Biotechnologies Inc., had assembled the necessary equipment necessary to allow the laboratory to commence the process of recombinant production of psilocybin - a process that engineers bacteria incorporating optimized biosynthetic genes from the Psilocybe cubensis mushroom thereby enabling the bacteria to act as a biological factory and synthesize psilocybin that is cost effective using simple building blocks.

The remaining 7 constituents have been less active and have not performed that well since the beginning of 2021, as follows: Nova Mentis Life Science  (LIBFF) +11.8% to $0.19/share; Pure Extracts Technologies (PRXTF) +9.8% to $0.56/share; Lobe Sciences (GTSIF) N/C @$0.10/share; Aion Therapeutic  (AION) N/C @ C$0.12/share; Better Plant Sciences (VEGGF) -15.4% to $0.11/share; M2Bio Sciences (WUHN) N/A $0.40/share and NeonMind Biosciences (NEON) N/A C$0.27/share

The above 12 psychedelic stocks went up 22.8%, on average, during the first three weeks of 2021.

Legend: Nano-Cap: Market Cap of $50M or less; N/C: No Change; N/A: (Not Applicable as not listed at end of 2020.)

For the record, 6 marginal psychedelic drug stocks are excluded from the above analysis as they are thinly traded and/or do not devote 100% of their efforts to the research and development of drugs based on psychedelic components. The 6 companies are: Graph Blockchain (REGRF), Minerco (MINE), Thoughtful Brands (PEMTF), Nutritional High (SPLIF), Codebase (BKLLF) and Hollister (HSTRF).